Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2020 Dec;31(12):1650-1663.
doi: 10.1016/j.annonc.2020.07.019. Epub 2020 Aug 12.

Bone health in cancer: ESMO Clinical Practice Guidelines

R Coleman  1 , P Hadji  2 , J-J Body  3 , D Santini  4 , E Chow  5 , E Terpos  6 , S Oudard  7 , Ø Bruland  8 , P Flamen  9 , A Kurth  10 , C Van Poznak  11 , M Aapro  12 , K Jordan  13 ; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Affiliations
Free article
Practice Guideline

Bone health in cancer: ESMO Clinical Practice Guidelines

R Coleman et al. Ann Oncol. 2020 Dec.
Free article
No abstract available

Keywords: Clinical Practice Guidelines; bone metastases; bone-targeted agents; cancer treatment-induced bone loss; diagnosis; follow-up; treatment.

PubMed Disclaimer

Conflict of interest statement

Disclosures RC has received consulting and/or speaker fees from Amgen, Astellas, Eisai, Genomic Health, Inbiomotion and Scancell, he is a patent holder for a biomarker developed by Inbiomotion and a former employee of prIME Oncology; PH has received consulting and speaker fees from Amgen, Pfizer, AstraZeneca, Eli Lilly, Gedeon-Richter, Janssen, Roche and Novartis and given expert testimony on behalf of Novartis; J-JB has received consulting and/or speaker fees from Amgen, Bayer and Sandoz; DS has received consulting and/or speaker fees from Amgen, Astellas, Novartis, Janssen, Roche, Bayer, Pfizer, Boehringer, Servier, Merck, Bristol-Myers Squibb and Merck Sharp & Dohme; EC has received speaker fees from Purdue; ET has received consulting and/or speaker fees from Amgen, Janssen, Celgene, Takeda and Novartis; SO has received consultant fees from Novartis, Pfizer, Astellas, Janssen, Sanofi, MSD, Bristol-Myers Squibb, Bayer, Ipsen and Roche; PF has received consulting and/or speaker fees from Algeta, Bayer, Sirtex, Ipsen, Novartis and AAA; CVP has received royalties from UpToDate and research funding from Bayer; MA has received consulting and/or speaker fees from Amgen, Bayer, Celgene, Roche and Novartis; KJ has received advisory board and/or honoraria for presentations for Merck Sharp & Dohme, Merck, Amgen, Hexal, Riemser, Helsinn, Tesaro, Kreussler, Voluntis, Pfizer, POMME-med, PharmaMar, Prime Oncology and Onko Update; OB and AK have declared no potential conflicts of interest.

Publication types